UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC 20549


                                  FORM 10-QSB



[X]   Quarterly Report pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

      For the quarterly period ended  February 28, 2005
                                      -----------------

[ ]   Transition Report pursuant to 13 or 15(d) of the Securities Exchange
      Act of 1934

      For the transition period                  to
                               ------------------   --------------------

      Commission File Number    333-107179
                            -----------------


                             XPENTION GENETICS, INC.
    ------------------------------------------------------------------------
       (Exact name of small Business Issuer as specified in its charter)


                               BAYVIEW CORPORATION
    ------------------------------------------------------------------------
     (Former name, former address and former fiscal year, if changed since
                                 last report)



          Nevada                                         98-0380519
---------------------------------             --------------------------------
(State or other jurisdiction of              (IRS Employer Identification No.)
 incorporation or organization)

10965 Elizabeth Drive
Conifer, CO                                               80433
----------------------------------------      --------------------------------
(Address of principal executive offices)           (Postal or Zip Code)


Issuer's telephone number, including area code:        (303) 908-4900
                                                ------------------------------

<PAGE>

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the issuer was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days [X] Yes [ ] No

State the number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date: 4,372,500 shares of $0.001 par value
common stock outstanding as of April 14, 2005.




<PAGE>

                          PART I FINANCIAL INFORMATION

Item 1.  Financial Statements


                             XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                          INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2005
                                   (Unaudited)
                            (Stated in U.S. Dollars)


<PAGE>

<TABLE>
<CAPTION>

                               XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                              INTERIM BALANCE SHEET
                                   (Unaudited)
                            (Stated in U.S. Dollars)



------------------------------------------------------------------------------- ------------------
                                                                                   FEBRUARY 28
                                                                                      2005
------------------------------------------------------------------------------- ------------------
<S>                                                                             <C>
ASSETS
Current
     Cash and cash equivalents                                                  $          387
=============================================================================== === ==============
LIABILITIES

Current
     Accounts payable and accrued liabilities                                   $        1,795
                                                                                --- --------------
STOCKHOLDERS' EQUITY

Share Capital
     Authorized:
         100,000,000 common shares, par value $0.001 per share
          10,000,000 preferred shares, par value $0.001 per share

     Issued and outstanding:
            3,272,500 common shares                                                      3,273

     Additional paid-in capital                                                         75,227
Deficit Accumulated During The Exploration Stage                                       (79,908)
                                                                                --- --------------
                                                                                        (1,408)
                                                                                --- --------------

                                                                                $           387
=============================================================================== === ==============
</TABLE>


                             See accompanying notes

                                      F-1

<PAGE>

<TABLE>
<CAPTION>


                               XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                            INTERIM STATEMENT OF LOSS
                                   (Unaudited)
                            (Stated in U.S. Dollars)


------------------------------------- ------------------ ------------------- -------------------  --------------
                                                                                                   CUMULATIVE
                                                                                                  PERIOD FROM
                                                                                                    DATE OF
                                                                                                   INCEPTION
                                                                                                  SEPTEMBER 5
                                        THREE MONTHS ENDED                NINE MONTHS ENDED         2002 TO
                                             FEBRUARY 28                     FEBRUARY 28          FEBRUARY 28
                                                2005                             2005
----------------------------------------------------------------------------------------------------------------
<S>                                  <C>                                  <C>                 <C>

Expenses
     Consulting fees                 $      15,000                        $     15,000        $          21,000
     Filing fees                              -                                  2,802                    2,802
     Mineral property exploration
       expenditures                           -                                   -                      19,100
     Mineral property option
       payments (Note 4)                      -                                  2,000                   11,500
     Office and sundry                        -                                     37                    4,879
     Professional fees                       8,291                              12,114                   22,744
                                       ------------------                    ----------------     --------------
Currency Gain                               (2,117)                             (2,117)                  (2,117)
Loss For The Period                    $     21,174                        $    27,034            $      79,908
                                       ==================                     ===============


Basic And Diluted Loss Per Share
                                       $         (0.01)                        $     (0.01)
                                       ==================                     ===============


Weighted Average Number Of Shares
  Outstanding
                                              3,272,500                            3,272,500
                                       ==================                     ===============
</TABLE>


                             See accompanying notes.

                                      F-2

<PAGE>

<TABLE>
<CAPTION>

                               XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                         INTERIM STATEMENT OF CASH FLOWS
                                   (Unaudited)
                            (Stated in U.S. Dollars)



-------------------------------------------------- -------------- ---------------- ----------------
                                                                                     CUMULATIVE
                                                                                      PERIOD FROM
                                                                                        DATE OF
                                                                                        INCEPTION
                                                                                     SEPTEMBER 5
                                                          NINE MONTHS ENDED             2002 TO
                                                             FEBRUARY 28              FEBRUARY 28
                                                        2005            2004            2005
                                                   -------------- ---------------- ----------------
<S>                                                 <C>            <C>              <C>

Cash Flows From Operating Activities
     Loss for the period                            $    (27,034)   $    (27,034)   $     (79,908)

Adjustments To Reconcile Net Loss To Net Cash
  Used By Operating Activities
     Accounts payable and accrued liabilities               175             (250)           1,795
     Prepaid Expenses                                         -              325                -
                                                      -----------   --------------  ---------------
                                                        (26,859)         (26,949)         (78,113)
                                                      -----------   --------------  ---------------

Cash Flows From Financing Activity
     Share capital issued                                  -               -               78,500
                                                      -----------   --------------  ---------------

(Decrease) Increase In Cash                               (26,859)        (26,949)            387

Cash, Beginning Of Period                                  27,246          54,613              -
                                                      -----------   --------------  ---------------

Cash, End Of Period                                 $        387    $      27,664    $        387
                                                      ===========   ==============  ===============
</TABLE>


                            See accompanying notes.

                                      F-3

<PAGE>

                            XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                      NOTES TO INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2005
                                   (Unaudited)
                            (Stated in U.S. Dollars)



1.   BASIS OF PRESENTATION

     The unaudited interim financial statements as of February 28, 2005 included
     herein  have  been  prepared  without  audit  pursuant  to  the  rules  and
     regulations of the Securities and Exchange Commission.  Certain information
     and footnote disclosures normally included in financial statements prepared
     in accordance with United States generally accepted  accounting  principles
     have been condensed or omitted pursuant to such rules and  regulations.  In
     the opinion of management,  all adjustments (consisting of normal recurring
     accruals)  considered necessary for a fair presentation have been included.
     It is suggested that these financial statements be read in conjunction with
     the May 31, 2004 audited financial statements and notes thereto.


2.   NATURE OF OPERATIONS

     a)  Organization

          The  Company  was  incorporated  in the State of  Nevada,  U.S.A.,  on
          September 5, 2002.

     b)  Exploration Stage Activities

          The Company has been in the exploration  stage since its formation and
          has not yet realized any revenues from its planned  operations.  It is
          primarily  engaged  in  the  acquisition  and  exploration  of  mining
          properties. Upon location of a commercial minable reserve, the Company
          expects to actively  prepare the site for its  extraction  and enter a
          development stage.

     c)  Going Concern

          The accompanying  financial statements have been prepared assuming the
          Company will continue as a going concern.

          As shown in the  accompanying  financial  statements,  the Company has
          incurred a net loss of $79,908 for the period from  September  5, 2002
          (inception) to February 28, 2005, and has no sales.  The future of the
          Company is  dependent  upon its ability to obtain  financing  and upon
          future  profitable  operations  from the  development  of its  mineral
          properties.  Management has plans to seek additional capital through a
          private  placement  and  public  offering  of its  common  stock.  The
          financial  statements do not include any  adjustments  relating to the
          recoverability  and  classification of recorded assets, or the amounts
          of and  classification  of liabilities  that might be necessary in the
          event the Company cannot continue in existence.

                                      F-4

<PAGE>



                               XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                      NOTES TO INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2005
                                   (Unaudited)
                            (Stated in U.S. Dollars)



3.   SIGNIFICANT ACCOUNTING POLICIES

     The  financial  statements  of the Company have been prepared in accordance
     with generally accepted accounting principles in the United States. Because
     a precise  determination  of many assets and  liabilities is dependent upon
     future  events,  the  preparation  of  financial  statements  for a  period
     necessarily  involves  the use of  estimates  which  have been  made  using
     careful judgment.

     The financial  statements  have,  in  management's  opinion,  been properly
     prepared within  reasonable  limits of materiality and within the framework
     of the significant accounting policies summarized below:

     a)  Mineral Property Option Payments and Exploration Costs

          The  Company  expenses  all  costs  related  to  the  maintenance  and
          exploration  of  mineral  claims in which it has  secured  exploration
          rights  prior to  establishment  of proven and probable  reserves.  To
          date, the Company has not  established  the commercial  feasibility of
          its exploration prospects, therefore, all costs are being expensed.

     b)  Use of Estimates

          The  preparation of financial  statements in conformity with generally
          accepted  accounting  principles requires management to make estimates
          and  assumptions  that  affect  the  reported  amounts  of assets  and
          liabilities,  and disclosure of contingent  assets and  liabilities at
          the date of the  financial  statements,  and the  reported  amounts of
          revenues and expenses for the reporting  period.  Actual results could
          differ from these estimates.

     c)  Income Taxes

          The Company has adopted  Statement of Financial  Accounting  Standards
          No. 109 -  "Accounting  for Income  Taxes" (SFAS 109).  This  standard
          requires  the use of an asset and  liability  approach  for  financial
          accounting,  and reporting on income taxes.  If it is more likely than
          not that some  portion  or all of a  deferred  tax  asset  will not be
          realized, a valuation allowance is recognized.


                                      F-5

<PAGE>


                               XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                      NOTES TO INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2005
                                   (Unaudited)
                            (Stated in U.S. Dollars)



3.   SIGNIFICANT ACCOUNTING POLICIES (Continued)

     d)  Basic and Diluted Loss Per Share

          In accordance with SFAS No. 128 - "Earnings Per Share", the basic loss
          per common share is computed by dividing net loss  available to common
          stockholders   by  the  weighted   average  number  of  common  shares
          outstanding.  Diluted  loss per common  share is  computed  similar to
          basic loss per common share except that the  denominator  is increased
          to include the number of additional common shares that would have been
          outstanding if the potential  common shares had been issued and if the
          additional  common  shares were  dilutive.  At February 28, 2005,  the
          Company has no stock equivalents that were  anti-dilutive and excluded
          in the earnings per share computation.


4.   MINERAL PROPERTY INTEREST

     The Company has entered into an option  agreement,  dated November 28, 2002
     and amended  November 13,  2003,  to acquire an 85% interest in two mineral
     claims located in the Sudbury Mining District in Ontario, Canada.

     In order to earn its  interests,  the Company made cash  payments  totaling
     $8,500 on signing and must incur exploration expenditures totaling $203,800
     as follows:

     Exploration expenditures:

     - $24,600 by February 28, 2005; - A further $179,200 by November 30, 2005.

     The properties are subject to a 1% net smelter return royalty.

     On November 30, 2004, the Company  further  amended the agreement to cancel
     the $24,600 expenditures  requirement originally  prescribed.  In addition,
     the  Company had paid  $19,100 to date and is  required to make  additional
     payments as follows:

     -   $2,000 upon execution of the amending agreement;
     -   Monthly payments of $2,000 for 12 months commencing on January 3, 2005.


                                      F-6

<PAGE>



                               XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                      NOTES TO INTERIM FINANCIAL STATEMENTS

                                FEBRUARY 28, 2005
                                   (Unaudited)
                            (Stated in U.S. Dollars)



5.   CONTINGENCY

     Mineral Property

     The Company's  mineral  property  interests have been acquired  pursuant to
     option  agreements.  In order to retain  its  interest,  the  Company  must
     satisfy the terms of the option agreements described in Note 4.

6.   SUBSEQUENT EVENTS

     In  February  2005,  the  Company  entered  into an  Agreement  and Plan of
     Reorganization  with Xpention,  Inc. whereby Xpention,  Inc. shall become a
     wholly-owned  subsidiary of the company.  The agreement was approved by the
     shareholders of both companies and was consummated on March 18, 2005.












                                      F-7

<PAGE>

Item 2. Management's Discussion and Analysis or Plan of Operation

FORWARD LOOKING STATEMENTS

This quarterly report contains forward-looking statements that involve risks and
uncertainties. We use words such as anticipate, believe, plan, expect, future,
intend and similar expressions to identify such forward-looking statements. You
should not place too much reliance on these forward-looking statements. Our
actual results are likely to differ materially from those anticipated in these
forward-looking statements for many reasons, including the risks faced by us
described in this Risk Factors section and elsewhere in this annual report.

Plan of Operation

During the interim period ended February 28, 2005, the Company amended its
option agreement whereby it is entitled to acquire a 85% interest, subject to a
1% net smelter returns royalty, in two mineral claims located in the Sudbury
Mining District, McLennan Township, Province of Ontario, Canada.

On January 3, 2005, the Company was required to pay an additional $2,000 in
order to keep the option respecting the Mac Len property in good standing.
However, it was unable to make this payment and the option is no longer in good
standing.

The plan of operation for the twelve months following the date of this quarterly
report is to finalize the acquisition of Xpention, Inc., a biotechnology firm
engaged in the development of a cancer test for canines and humans.

Results Of Operations For Period Ending February 28, 2005

The Company did not earn any revenues during the three-month period ending
February 28, 2005. The Company incurred operating expenses in the amount of
$21,174 during the three-month period ended February 28, 2005. This amount
consisted primarily of professional fees of $8,291, consulting fees of $15,000,
and currency gain of $2,117.

The Company has not attained profitable operations and is dependent upon
obtaining financing in order to proceed with any asset acquisition. For these
reasons, there is substantial doubt that we will be able to continue as a going
concern.

At February 28, 2005, cash on hand was $387 and accounts payable and accrued
liabilities were $1,795.


Item 3.  Controls and Procedures

Evalution of Disclosure Controls

Management evaluated the effectiveness of the disclosure controls and procedures
as of the end at February 28, 2005. This evaluation was conducted by the chief
executive officer and principal accounting officer.

<PAGE>

Disclosure controls are controls and other procedures that are designed to
ensure that information that is required to disclose in the reports filed
pursuant to the Securities Exchange Act of 1934 is recorded, processed,
summarized and reported.

Limitations on the Effective of Controls

Management does not expect that the disclosure controls or the internal controls
over financial reporting will prevent all error and fraud. A control system, no
matter how well conceived and operated, can provide only reasonable, but no
absolute, assurance that the objectives of a control system are met. Further,
any control system reflects limitations on resources, and the benefits of a
control system must be considered relative to its costs. These limitations also
include the realities that judgments in decision-making can be faulty and that
breakdowns can occur because of simple error or mistake. Additionally, controls
can be circumvented by the individual acts of some persons, by collusion of two
or more people or by management override of a control. A design of a control
system is also based upon certain assumptions about potential future conditions;
over time, controls may become inadequate because of changes in conditions, or
the degree of compliance with the policies or procedures may deteriorate.
Because of the inherent limitations in a cost-effective control system,
misstatements due to error or fraud may occur and may not be detected.

Conclusions

Based upon his evaluation of the controls, the chief executive officer and
principal accounting officer has concluded that, subject to the limitations
noted above, the disclosure controls are effective providing reasonable
assurance that material information relating to the Company is made known to
management on a timely basis during the period when the reports are being
prepared. There were no changes in the internal controls that occurred during
the quarter covered by this report that have materially affected, or are
reasonably likely to materially affect the internal controls.

                           PART II- OTHER INFORMATION

Item 1.  Legal Proceedings

The Company is not a party to any pending legal proceeding. Current management
is not aware of any threatened litigation, claims or assessments.


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

The Company did not issue any securities during the quarter ended February 28,
2005.


Item 3. Defaults Upon Senior Securities

         None.

<PAGE>

Item 4. Submission of Matters to a Vote of Security Holders

         None.


Item 5. Other Information

         None.


Item 6. Exhibits

31    Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to Section 302 of the Sarbanes-Oxley Act of 2002

32    Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002

<PAGE>

                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Dated:  April 19, 2005

                                        Xpention Genetics, Inc.

                                        /s/ David Kittrell
                                        ------------------------------
                                        David Kittrell, President